Trade Moderna Inc ^MRNA

No cure, no approved vaccine, no antiviral: Why the Hantavirus threat is raising alarm again | Explained

Hantavirus fears put Moderna vaccine efforts in focus

Moderna Hantavirus Program Draws New Focus As Shares Outpace Targets

5 Insightful Analyst Questions From Moderna's Q1 Earnings Call

Health Care Down as Vaccine Bets Stall - Health Care Roundup | Morningstar

Moderna Stock Is Surging on Hantavirus Threats. Its Chart Offers a Harsh Dose of Reality.

New Moderna Short Target After Hantavirus Vaccine News

Here's how much Moderna's stock has rallied off renewed focus on hantavirus research | Morningstar

Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges

Moderna shares jump as it reveals it has been researching vaccines against hantaviruses

Moderna Extends Rally After Two More Cruise Ship Passengers Test Positive For Hantavirus

Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging. - AOL

Moderna stock surges 22% in 2 days as investors monitor hantavirus outbreak

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Premarket Winners: Moderna (MRNA), Intel (INTC), and Micron (MU) Rally on Monday

Moderna stock extends gains on hantavirus research

Hantavirus cases spark surge in pharma, biotech stocks - here's why

Best Medical Stocks To Watch Today - May 11th - Daily Political

Moderna (MRNA) Shares Surge 8% on Hantavirus Vaccine Research

Moderna shares jump 8% after U.S. national tests positive for hantavirus

Moderna (MRNA) Sees Gains Amid Market Uncertainty

Top Biotech Stocks To Consider - May 10th - Stock Observer

Personalis, Inc. (NASDAQ:PSNL) Q1 2026 Earnings Call Transcript

Moderna (MRNA) Gains Attention Amid Rising Virus Concerns

MRNA Stock Alert: Moderna Surges on Hantavirus Vaccine Hopes

Moderna (MRNA) Advances Hantavirus Vaccine Development Amid Renewed Interest

Moderna (MRNA) Stock Jumps 16% Following Positive Flu Vaccine Results and Wall Street Upgrades

Moderna (NASDAQ:MRNA) Trading 12.6% Higher - Should You Buy?

Moderna Flags Work on Hantavirus Vaccines Before Cruise Outbreak

Investors Buy Large Volume of Moderna Call Options (NASDAQ:MRNA) - Zolmax

Brookline Capital Markets Forecasts Moderna FY2026 Earnings - Stock Observer

Moderna, Vir among early 2026 top infectious disease gainers | BioWorld

Is Wall Street Bullish or Bearish on Moderna Stock?

Paranoia, turmoil and backlash: Inside the FDA under Marty Makary

Moderna Shareholders OK Directors, Executive Pay Votes and Ernst & Young as 2026 Auditor at AGM - Stock Observer

Has The Market Rerated Moderna (MRNA) Too Quickly After Its Recent Share Price Surge?

Biotech Stocks To Add to Your Watchlist - May 6th - Daily Political

Assessing Moderna (MRNA) Valuation After Strong Q1 Results And New EU Vaccine And Oncology Milestones

Brookline Capital Markets Weighs in on Moderna Q2 Earnings - Stock Observer

Sigma Planning Corp Purchases New Holdings in Moderna, Inc. $MRNA - Stock Observer

Moderna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals | Markets Insider

MRNA Maintained by RBC Capital -- Price Target Raised to $38.00

Abbas Hussain Sells 5,682 Shares of Moderna (NASDAQ:MRNA) Stock - Stock Observer

Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era

Moderna (NASDAQ:MRNA) Posts Quarterly Earnings Results - Stock Observer

Moderna (MRNA) Loss Of US$2.8b Keeps Bearish Narratives In Focus

Moderna Q1 Earnings Call Highlights - Stock Observer

Moderna, Inc. (NASDAQ:MRNA) Q1 2026 Earnings Call Transcript

Vanguard Group Inc. Purchases 399,487 Shares of Moderna, Inc. $MRNA - Stock Observer

A Look At Moderna (MRNA) Valuation After Q1 2026 Earnings And New Vaccine Approvals

Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges

Q1 2026 Moderna Inc Earnings Call Transcript

Moderna, Inc. (NASDAQ:MRNA) Receives $33.87 Average PT from Analysts - Daily Political

Moderna price target raised to $49 from $43 at Goldman Sachs | Markets Insider

Moderna (NASDAQ:MRNA) Announces Earnings Results

Health Care Up as Obesity-Drug Makers Regain Momentum - Health Care Roundup | Morningstar

S&P 500 and Nasdaq Surge to All-Time Highs Powered by Strong Earnings Reports

Is Moderna (MRNA) Overvalued After Q1 2026? EPS -$3.40 Miss vs -$2. ...

Moderna's Strong Vaccine Sales Outside US Far Surpass Estimates

Moderna Stock Rises After Earnings. Covid Vaccine Revenue Is a Growth Driver Again.

Moderna (MRNA) Surges Nearly 8% as Q1 Revenue Crushes Wall Street Forecasts

Moderna Stock Spikes After Earnings. Covid Vaccine Revenue Is a Growth Driver Again.

Moderna, Inc Q1 Loss Climbs

MRNA shares: Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimates - The Economic Times

Moderna tops revenue estimates on stronger international COVID vaccine sales

Coronavirus - Articles | BioWorld

Moderna (MRNA) Prepares for Earnings Amid Revenue Challenges

Moderna loses key mRNA patent in European vaccine fight

Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026

Best Biotech Stocks To Add to Your Watchlist - April 28th - Daily Political

CureVac targets Moderna with 10-patent suit over Spikevax

Moderna's H5N1 Vaccine Trial Draws Support As Valuation Stays Stretched

Biotech Visionary's Resilience Drives Platinum Fund Success

Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman

Best biotech stock picks, Moderna investment explained by Platinum Asset Management's Bianca Ogden

CureVac Patent Suit Targets Moderna's Spikevax Covid-19 Shots

Moderna, Inc. (NASDAQ:MRNA) Given Average Recommendation of "Reduce" by Brokerages

What If the FDA Were Eliminated?

M&T Bank Corp Acquires 240,400 Shares of Moderna, Inc. $MRNA

CureVac sues Moderna for patent infringement over COVID-19 vaccines

Assessing Moderna (MRNA) Valuation After European Approval Of First Flu Plus COVID Combination Vaccine

Moderna (MRNA) Expected to Announce Earnings on Friday

Moderna News Ties Combo Vaccine Approval To Broader mRNA Prospects

Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran

Bird flu vaccine trial begins to fight 'real possibility' of virus threat for humans

First bird flu mRNA vaccine enters late-stage trial

Biotech Stocks To Consider - April 19th - Stock Observer

Moderna (MRNA) Advances with Phase 3 Study of Influenza Vaccine

Post-vaccine inflammation tracking: validation of a novel individualized digital inflammatory biomarker relative to serum biomarkers

Moderna initiates Phase 3 study of mRNA Pandemic influenza vaccine | Markets Insider

Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth